1-8 of 8
Joohyuk Sohn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Komal L. Jhaveri, Meritxell Bellet, Nicholas C. Turner, Sherene Loi, Aditya Bardia, Valentina Boni, Joohyuk Sohn, Tomas G. Neilan, Rafael Villanueva-Vázquez, Peter Kabos, Laura García-Estévez, Elena López-Miranda, J. Alejandro Pérez-Fidalgo, Jose M. Pérez-García, Jiajie Yu, Jill Fredrickson, Heather M. Moore, Ching-Wei Chang, John W. Bond, Jennifer Eng-Wong, Mary R. Gates, Elgene Lim
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 754–766.
https://doi.org/10.1158/1078-0432.CCR-23-1796
Published: 16 February 2024
View article titled, Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
Open the PDF for Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Sara M. Tolaney, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva-Maria Grischke, Antonio Llombart-Cussac, Hatem Soliman, Hong Wang, Sameera Wijayawardana, Valerie M. Jansen, Lacey M. Litchfield, George W. Sledge, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4587.
https://doi.org/10.1158/1078-0432.CCR-22-2874
Published: 14 October 2022
View article titled, Correction: Clinical Significance of <em>PIK3CA</em> and <em>ESR1</em> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
Open the PDF for Correction: Clinical Significance of <em>PIK3CA</em> and <em>ESR1</em> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant in another window
Journal Articles

Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Sara M. Tolaney, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva-Maria Grischke, Antonio Llombart-Cussac, Hatem Soliman, Hong Wang, Sameera Wijayawardana, Valerie M. Jansen, Lacey M. Litchfield, George W. Sledge, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1500–1506.
https://doi.org/10.1158/1078-0432.CCR-21-3276
Published: 14 April 2022
View article titled, Clinical Significance of <em>PIK3CA</em> and <em>ESR1</em> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
Open the PDF for Clinical Significance of <em>PIK3CA</em> and <em>ESR1</em> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant in another window
Includes: Supplementary data
Journal Articles

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Fatima Cardoso, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K. Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi El-Saghir, Ruth O'Regan, Claudia Gasch, Nadia Solovieff, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yan Ji, Debu Tripathy
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 851–859.
https://doi.org/10.1158/1078-0432.CCR-21-3032
Published: 01 March 2022
View article titled, Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Open the PDF for Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer

Patrick Neven, Stephen R.D. Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva-Maria Grischke, PierFranco Conte, Yi Lu, Nadine Haddad, Karla C. Hurt, Antonio Llombart-Cussac, George W. Sledge
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5801–5809.
https://doi.org/10.1158/1078-0432.CCR-20-4685
Published: 01 November 2021
View article titled, MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>−</sup>-Advanced Breast Cancer
Open the PDF for MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>−</sup>-Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer

Yen-Shen Lu, Keun Seok Lee, Tsu-Yi Chao, Ling-Ming Tseng, Imjai Chitapanarux, Shin-Cheh Chen, Chien-Ting Liu, Joohyuk Sohn, Jee Hyun Kim, Yuan-Ching Chang, Youngsen Yang, Kanjana Shotelersuk, Kyung Hae Jung, Roberta Valenti, Cassandra Slader, Melissa Gao, Yeon Hee Park
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (2): 408–417.
https://doi.org/10.1158/1078-0432.CCR-20-1008
Published: 19 January 2021
View article titled, A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer
Open the PDF for A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy

Padmanee Sharma, Joohyuk Sohn, Sang Joon Shin, Do-Youn Oh, Bhumsuk Keam, Hyo Jin Lee, Marco Gizzi, Ewa Kalinka, Filip Y.F.L. de Vos, Dario Ruscica, Salvatore Ferro, Feng Xiao, Paul Baverel, Cecil Chi-Keung Chen, Kobby Asubonteng, Nassim Morsli, Luc Dirix
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (1): 61–70.
https://doi.org/10.1158/1078-0432.CCR-19-1635
Published: 03 January 2020
View article titled, Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy
Open the PDF for Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study

Shin-Ae Kang, Jye Swei Guan, Hock Jin Tan, Tinghine Chu, Aye Aye Thike, Cristina Bernadó, Joaquín Arribas, Chow Yin Wong, Puay Hoon Tan, Mihir Gudi, Thomas Choudary Putti, Joohyuk Sohn, Swee Ho Lim, Soo Chin Lee, Yoon Pin Lim
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (8): 2588–2600.
https://doi.org/10.1158/1078-0432.CCR-18-3228
Published: 15 April 2019
View article titled, Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study
Open the PDF for Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study in another window
Includes: Supplementary data